Edwards Lifesciences exec sells 619 shares in plan
Edwards Lifesciences Corp corporate vice president Daniel J. Lippis exercised and sold a small block of shares under a pre-planned program.
Rhea-AI Filing Summary
Edwards Lifesciences Corp corporate vice president Daniel J. Lippis exercised and sold a small block of shares under a pre-planned program. He exercised employee stock options to acquire 619 shares of common stock at $72.68 per share, then sold 619 shares in an open-market sale at a weighted average price of $91.4002 per share.
The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2026, indicating they were pre-scheduled. After these trades, Lippis directly holds about 40,410.9103 shares of common stock and 5,571 employee stock options.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 619 shares ($12K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Lippis Daniel J.
Role
CVP, TAVR
Sold
619 shs ($57K)
Approx. gross sale proceeds
$57K
Approx. exercise cost
$45K
Approx. pre-tax spread
$12K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (Right to Acquire) | 619 | $0.00 | $0.00 |
| Exercise | Common Stock | 619 | $72.68 | $45K |
| Sale | Common Stock | 619 | $91.4002 | $57K |
Holdings After Transaction:
Employee Stock Option (Right to Acquire) — 5,571 contracts (Direct);
Common Stock — 40,410.9103 shares (Direct)
Footnotes (2)
- F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026.
- F2. This transaction was executed in multiple trades at prices ranging from $91.185 to $91.650. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Shares sold: 619 shares
Sale price: $91.4002 per share
Option exercise shares: 619 shares
+5 more
8 metrics
Shares sold
619 shares
Open-market sale on June 30, 2026
Sale price
$91.4002 per share
Weighted average sale price
Option exercise shares
619 shares
Employee stock option exercise on June 30, 2026
Option exercise price
$72.68 per share
Employee Stock Option (Right to Acquire)
Common shares held after
40,410.9103 shares
Direct common stock holdings post-transaction
Options remaining
5,571 options
Employee stock options after exercise
10b5-1 plan adoption date
February 13, 2026
Plan governing these trades
Option expiration
May 6, 2027
Expiration date of exercised option grant
Key Terms
Rule 10b5-1 trading plan, Employee Stock Option (Right to Acquire), open-market sale, derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Employee Stock Option (Right to Acquire) financial
"security_title": "Employee Stock Option (Right to Acquire)""
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
weighted average sale price financial
"The price reported above reflects the weighted average sale price."
FAQ
What insider transactions did EW executive Daniel J. Lippis report?
Daniel J. Lippis reported exercising employee stock options for 619 Edwards Lifesciences shares at $72.68 each and selling 619 shares in an open-market transaction at a weighted average of $91.4002 per share, all on June 30, 2026.
Was the Edwards Lifesciences (EW) insider sale part of a 10b5-1 plan?
Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted by Daniel J. Lippis on February 13, 2026. Such plans pre-schedule trades, making their timing more routine and less reflective of short-term views.
What stock options does the EW executive still retain after exercising 619 options?
After exercising 619 employee stock options, Daniel J. Lippis retains 5,571 options. These options carry a conversion or exercise price of $72.68 per share and are scheduled to expire on May 6, 2027, according to the Form 4 details.
What prices were involved in the Edwards Lifesciences (EW) insider trades?
The option exercise price was $72.68 per share, while the sale transaction’s weighted average price was $91.4002 per share. Individual sale trades occurred in a range between $91.185 and $91.650, based on the filing footnote.
AI-generated analysis. How Rhea-AI works. Not financial advice.
